secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000950170-25-025232
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen reports robust splicing correction in DM1 trial; 29.1% mean correction at 10 mg/kg single dose
--------------------------------------------------------------------------------

- Mean splicing correction of 12.3% (5 mg/kg, n=6) and 29.1% (10 mg/kg, n=4) at 28 days post single dose.
- Favorable emerging safety profile; one treatment-related SAE of abdominal pain potentially confounded.
- Cash $120.2M as of Dec 31, 2024, expected to fund operations into 2026.
- Net loss $90.0M for FY2024 ($2.85/share) vs $78.6M ($3.30/share) in FY2023.
- 15 mg/kg cohort results expected H2 2025; CONNECT1-EDO51 10 mg/kg fully enrolled with results Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017025025232/0000950170-25-025232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017025025232/pepg-20250224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-025232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer